Update 1 (09-2015)

Our studies performed so far suggest that KRAS positive mucinous adenocarcinomas are responsive to MEK and PI3K inhibition and that bilateral blockade of MEK and PI3K is more effective than single agent treatment in reducing tumor growth.

Update 2 (03-2016)

Our studies performed so far suggest that KRAS positive mucinous adenocarcinomas are responsive to MEK and PI3K inhibition and that bilateral blockade of MEK and PI3K is more effective than single agent treatment in reducing tumor growth.

Update 3 (09-2016)

Our studies performed so far suggest that KRAS positive mucinous adenocarcinomas are responsive to MEK and PI3K inhibition and that bilateral blockade of MEK and PI3K is more effective than single agent treatment in reducing tumor growth.

Update 4 (04-2017)

Our studies performed so far suggest that KRAS positive mucinous adenocarcinomas are responsive to MEK and PI3K inhibition and that bilateral blockade of MEK and PI3K is more effective than single agent treatment in reducing tumor growth.